In the BioHarmony Drug Report Database

"Preview" Icon

Reteplase

Retavase, Rapilysin (reteplase) is an enzyme pharmaceutical. Reteplase was first approved as Retavase on 1996-08-29. It is used to treat myocardial infarction and ventricular dysfunction in the USA. It has been approved in Europe to treat myocardial infarction.

 

Trade Name

 

Rapilysin
 

Common Name

 

reteplase
 

ChEMBL ID

 

CHEMBL2107885
 

Indication

 

myocardial infarction, ventricular dysfunction
 

Drug Class

 

Enzymes: tissue-type plasminogen activators

Image (chem structure or protein)

Reteplase structure rendering